Monoclonal antibody for isolation of LRP1 for treatment of neurodegenerative diseases
This technology is a monoclonal antibody that can isolate low-density lipoprotein receptor-related protein 1 (LRP1) from biological tissue for use in therapies for neurodegenerative diseases.
Unmet Need: Method for purifying LRP1 from different host species
Low-density lipoprotein receptor-related protein 1 (LRP1) is an important protein implicated in the development of brain plaques in neurodegenerative diseases, with roles in the uptake and regulation of other proteins that create plaques on the brain and reduce cognitive function. Although LRP1 is critical for preventing the development of these plaques, there are currently no methods to genetically engineer LRP1 for therapeutic use. Current methods for the purification of LRP1 use in vitro expression systems, which are expensive and have limited yield. There is a need for a method for purifying LRP1 to enable large-scale production of LRP1 across different hosts for the development of therapeutics for treating neurodegenerative diseases.
The Technology: Monoclonal antibody that isolates LRP1 from native tissue
This technology is a monoclonal antibody that targets low-density lipoprotein receptor-related protein 1 (LRP1). It allows for the isolation of the LRP1 receptor using immunoaffinity chromatography. This monoclonal antibody targets a conserved epitope on LRP1, allowing for purification from different species, including human, bovine, and murine tissues. This technology has the potential to improve research in and treatments of currently incurable neurodegenerative diseases by producing larger quantities of LRP1 across different host species.
Applications:
- Therapeutics for neurodegenerative diseases
- Therapeutics for other diseases associated with LRP1
- Research tool for studying neurodegenerative diseases
- Research tool for understanding the molecular mechanisms of LRP1
Advantages:
- Capable of purifying LRP1 natively from human, bovine, and murine tissues
- Capable of purifying larger amounts of LRP1 compared to current methods
- Does not require genetic engineering
- Uses a common chromatographic immunoassay
Lead Inventor:
Related Publications:
Tech Ventures Reference:
IR CU25221
Licensing Contact: Kristin Neuman